Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities    
Net loss $ (56,171) $ (28,078)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization expense 1,936 4
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 13,859 9,134
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 1,132 465
APA-RDx: Issue common stock - settle installment payment 653
Changes in operating assets and liabilities:    
Accounts receivable 183 (200)
Prepaid expenses and other current assets 1,163 (2,088)
Accounts payable (445) (665)
Accrued expenses and other current liabilities 333 926
Accrued CWRU License Agreement Fee (223)
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee 7,672 3,057
Net cash flows used in operating activities (29,685) (17,668)
Cash flows from investing activities    
Purchase of equipment (908) (862)
Asset acquisition (3,200)
Net cash flows used in investing activities (4,108) (862)
Cash flows from financing activities    
Proceeds – issue of common stock – initial public offering 70,000
Proceeds – issue of common stock – Committed Equity Facility 1,807
Payment – offering costs – initial public offering (5,664)
Proceeds – exercise of stock options 695
Proceeds – issue common stock – Employee Stock Purchase Plan 109
Proceeds – Due To: PAVmed Inc. - working capital cash advances 7,739
Net cash flows provided by financing activities 2,611 72,075
Net increase (decrease) in cash (31,182) 53,545
Cash, beginning of period 53,656 111
Cash, end of period $ 22,474 $ 53,656